Distributor | sciencenewsnet.in

Breaking News

Additional comments on extracellular vesicles derived from mesenchymal stem cells mediate extracellular matrix remodeling in osteoarthritis

Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury

Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease

Study finds targeting inflammation may not help reduce liver fibrosis in MAFLD

UF scientists study how to bring you ‘climate-smart coffee’

Moffitt Study Uncovers Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma

Chula hosted “The Second Chulalongkorn University President’s Distinguished Speakers” a Special Lecture on “Revolutionizing the Future: An Exclusive Talk with “Andrew Ng” on Opportunities and Business Preparedness” by the World’s Influential AI Exper

Cleaning the window of opportunity: Towards a typology of sustainability entrepreneurs

Does information disclosure alleviate overcrowding? An empirical study based on large-scale COVID-19 nucleic acid test

Researchers develop state-of-the-art device to make artificial intelligence more energy efficient

27 Jul, 2024

Technoclone Receives US FDA Marketing Authorization For The First ADAMTS13 Activity Diagnostic Test

March 5, 2024 sarah JonasAnnouncement

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, world-leading producer of diagnostic tests, equipment, and research products in the field of blood clotting and its exclusive distributor in the USA, DiaPharma Group, Inc., are pleased to announce that the US Food and Drug Administration (FDA) granted De Novo marketing authorization for Technozym ADAMTS13 Activity ELISA.